Track topics on Twitter Track topics that are important to you
Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating its efficacy in treating patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.
Zykadia, an orally-administered selective inhibitor of anaplastic lymphoma kinase, showed a significant improvement in progression-free survival in previously untreated patients compared to standard chemotherapy.
Original Article: Novartis’ Zykadia smashes Phase III target for lung cancerNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...